QQQ   355.55 (+0.68%)
AAPL   182.00 (+0.79%)
MSFT   328.26 (+0.92%)
META   265.44 (+0.33%)
GOOGL   123.09 (+0.78%)
AMZN   124.44 (+0.15%)
TSLA   247.15 (+5.23%)
NVDA   391.10 (+1.56%)
NIO   7.85 (+0.77%)
BABA   85.93 (-0.24%)
AMD   125.43 (+3.62%)
T   16.02 (-0.31%)
F   13.77 (+1.40%)
MU   65.52 (+0.31%)
CGC   0.67 (-3.62%)
GE   105.99 (-0.08%)
DIS   92.06 (-0.51%)
AMC   4.75 (+1.50%)
PFE   38.96 (-0.33%)
PYPL   63.71 (-0.83%)
NFLX   423.81 (+3.53%)
QQQ   355.55 (+0.68%)
AAPL   182.00 (+0.79%)
MSFT   328.26 (+0.92%)
META   265.44 (+0.33%)
GOOGL   123.09 (+0.78%)
AMZN   124.44 (+0.15%)
TSLA   247.15 (+5.23%)
NVDA   391.10 (+1.56%)
NIO   7.85 (+0.77%)
BABA   85.93 (-0.24%)
AMD   125.43 (+3.62%)
T   16.02 (-0.31%)
F   13.77 (+1.40%)
MU   65.52 (+0.31%)
CGC   0.67 (-3.62%)
GE   105.99 (-0.08%)
DIS   92.06 (-0.51%)
AMC   4.75 (+1.50%)
PFE   38.96 (-0.33%)
PYPL   63.71 (-0.83%)
NFLX   423.81 (+3.53%)
QQQ   355.55 (+0.68%)
AAPL   182.00 (+0.79%)
MSFT   328.26 (+0.92%)
META   265.44 (+0.33%)
GOOGL   123.09 (+0.78%)
AMZN   124.44 (+0.15%)
TSLA   247.15 (+5.23%)
NVDA   391.10 (+1.56%)
NIO   7.85 (+0.77%)
BABA   85.93 (-0.24%)
AMD   125.43 (+3.62%)
T   16.02 (-0.31%)
F   13.77 (+1.40%)
MU   65.52 (+0.31%)
CGC   0.67 (-3.62%)
GE   105.99 (-0.08%)
DIS   92.06 (-0.51%)
AMC   4.75 (+1.50%)
PFE   38.96 (-0.33%)
PYPL   63.71 (-0.83%)
NFLX   423.81 (+3.53%)
QQQ   355.55 (+0.68%)
AAPL   182.00 (+0.79%)
MSFT   328.26 (+0.92%)
META   265.44 (+0.33%)
GOOGL   123.09 (+0.78%)
AMZN   124.44 (+0.15%)
TSLA   247.15 (+5.23%)
NVDA   391.10 (+1.56%)
NIO   7.85 (+0.77%)
BABA   85.93 (-0.24%)
AMD   125.43 (+3.62%)
T   16.02 (-0.31%)
F   13.77 (+1.40%)
MU   65.52 (+0.31%)
CGC   0.67 (-3.62%)
GE   105.99 (-0.08%)
DIS   92.06 (-0.51%)
AMC   4.75 (+1.50%)
PFE   38.96 (-0.33%)
PYPL   63.71 (-0.83%)
NFLX   423.81 (+3.53%)

UroGen Pharma (URGN) Stock Forecast, Price & News

$11.35
+0.29 (+2.62%)
(As of 02:02 PM ET)
Compare
Today's Range
$10.78
$11.42
50-Day Range
$8.75
$14.29
52-Week Range
$6.05
$16.11
Volume
81,249 shs
Average Volume
152,344 shs
Market Capitalization
$258.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

UroGen Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
50.1% Upside
$16.50 Price Target
Short Interest
Bearish
4.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.34) to ($3.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

345th out of 986 stocks

Pharmaceutical Preparations Industry

154th out of 481 stocks


URGN stock logo

About UroGen Pharma (NASDAQ:URGN) Stock

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Stock News Headlines

Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Recap: UroGen Pharma Q1 Earnings
Goldman Sachs Reaffirms Their Hold Rating on Urogen Pharma (URGN)
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle
More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...
H.C. Wainwright Reaffirms Their Buy Rating on Urogen Pharma (URGN)
See More Headlines

URGN Price History

URGN Company Calendar

Last Earnings
3/16/2023
Today
6/09/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:URGN
Fax
N/A
Employees
195
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+49.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-109,780,000.00
Net Margins
-163.25%
Pretax Margin
-162.02%

Debt

Sales & Book Value

Annual Sales
$64.36 million
Book Value
($3.93) per share

Miscellaneous

Free Float
19,830,000
Market Cap
$251.50 million
Optionable
Optionable
Beta
0.75

Key Executives

  • Elizabeth BarrettElizabeth Barrett
    President, Chief Executive Officer & Director
  • Dong Kim
    Chief Financial & Accounting Officer
  • Marina Konorty
    Executive Vice President-Research & Development
  • Mark P. SchoenbergMark P. Schoenberg
    Chief Medical Officer
  • Moran Mieron
    Director-Research & Pre-Clinical Affairs













URGN Stock - Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" URGN shares.
View URGN analyst ratings
or view top-rated stocks.

What is UroGen Pharma's stock price forecast for 2023?

2 analysts have issued twelve-month price objectives for UroGen Pharma's shares. Their URGN share price forecasts range from $10.00 to $23.00. On average, they anticipate the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 49.2% from the stock's current price.
View analysts price targets for URGN
or view top-rated stocks among Wall Street analysts.

How have URGN shares performed in 2023?

UroGen Pharma's stock was trading at $8.87 on January 1st, 2023. Since then, URGN stock has increased by 24.7% and is now trading at $11.06.
View the best growth stocks for 2023 here
.

Are investors shorting UroGen Pharma?

UroGen Pharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 944,700 shares, an increase of 29.3% from the April 30th total of 730,500 shares. Based on an average daily volume of 175,400 shares, the days-to-cover ratio is presently 5.4 days. Currently, 4.8% of the company's shares are sold short.
View UroGen Pharma's Short Interest
.

When is UroGen Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our URGN earnings forecast
.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings data on Thursday, March, 16th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by $0.10. The business earned $18.09 million during the quarter, compared to analysts' expectations of $18.25 million.

What ETF holds UroGen Pharma's stock ?

ARK Israel Innovative Technology ETF holds 269,775 shares of URGN stock, representing 2.49% of its portfolio.

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.08%), BlackRock Inc. (1.25%), ARK Investment Management LLC (1.19%), Bank of America Corp DE (0.57%), State Street Corp (0.53%) and Meitav Investment House Ltd. (0.47%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg, Molly Henderson and Peter P Pfreundschuh.
View institutional ownership trends
.

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $11.06.

How much money does UroGen Pharma make?

UroGen Pharma (NASDAQ:URGN) has a market capitalization of $251.50 million and generates $64.36 million in revenue each year. The company earns $-109,780,000.00 in net income (profit) each year or ($4.83) on an earnings per share basis.

How many employees does UroGen Pharma have?

The company employs 195 workers across the globe.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for the company is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com.

This page (NASDAQ:URGN) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -